The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration-Reference-Cited by-同舟云学术

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

Published:2023-05-17 Issue:5 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Xiao Meng A.¹²,Cleyle Jenna¹²,Yoo Sunbin¹²,Forrest Mekayla¹²,Krullaars Zoë³^ORCID,Pham Hanh Thi¹²,Mesplède Thibault¹²^ORCID

Affiliation:

1. McGill AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec, Canada

2. Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montréal, Quebec, Canada

3. Viroscience Department, Erasmus Medical Center, Rotterdam, Zuid-Holland, The Netherlands

Abstract

Human immunodeficiency virus (HIV) treatment with antiretroviral regimens containing integrase strand transfer inhibitors such as dolutegravir (DTG) and bictegravir (BIC) offers high levels of protection against the development of drug resistance mutations. Despite this, resistance to DTG and BIC can occur through the development of the R263K integrase substitution.

Funder

Gouvernement du Canada | Canadian Institutes of Health Research

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01386-22

Reference39 articles.

1. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

2. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

3. Development of Antiretroviral Drug Resistance